Related Experiment Video
Updated: Jun 26, 2026
09:41
Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
Published on: January 20, 2023
[Targeting B cells in multiple sclerosis. Current concepts and strategies]
T Menge1, H-C Büdingen, M C Dalakas
1Neurologische Klinik, Heinrich-Heine-Universität, Moorenstrasse 5, 40225, Düsseldorf, Deutschland.
Der Nervenarzt
|February 4, 2009
Summary
Rituximab, a B-cell depleting therapy, shows promising results for multiple sclerosis (MS). It effectively reduces MRI lesions and clinical relapses, offering new hope for MS patients.
Area of Science:
- Neuroimmunology
- Autoimmune diseases
- Central Nervous System (CNS) disorders
Context:
- Multiple sclerosis (MS) is a chronic inflammatory demyelinating autoimmune disease of the CNS.
- B cells are increasingly recognized as key players in MS immunopathogenesis.
- B cells function beyond antibody production, acting as antigen-presenting cells and secreting proinflammatory cytokines.
Purpose:
- To review the role of autoreactive B cells in multiple sclerosis.
- To analyze B-cell-depleting treatment studies in MS.
- To discuss future B-cell-directed therapeutic strategies for MS.
Summary:
- Rituximab, a CD20-targeting monoclonal antibody, depletes B cells, sparing stem and plasma cells.
- A recent phase II study demonstrated Rituximab's efficacy in MS, meeting primary MRI endpoints and reducing relapse rates.
- The study highlights the therapeutic potential of targeting B cells in MS management.
Impact:
- Provides a comprehensive overview of B-cell involvement in MS.
- Evaluates the clinical efficacy of B-cell depletion therapy in MS patients.
- Informs the development of novel B-cell-targeted therapies for MS.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:22iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.